M. R. Abboud Et Al. , "Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study," 65th American Society of Hematology (ASH) Annual Meeting and Exposition , vol.142, San Diego, United States Of America, pp.272, 2023
Abboud, M. R. Et Al. 2023. Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study. 65th American Society of Hematology (ASH) Annual Meeting and Exposition , (San Diego, United States Of America), 272.
Abboud, M. R., Cançado, R. D., De Montalembert, M., Smith, W. R., Rimawi, H., Voskaridou, E., ... GÜVENÇ, B.(2023). Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study . 65th American Society of Hematology (ASH) Annual Meeting and Exposition (pp.272). San Diego, United States Of America
Abboud, Miguel Et Al. "Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study," 65th American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, United States Of America, 2023
Abboud, Miguel R. Et Al. "Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study." 65th American Society of Hematology (ASH) Annual Meeting and Exposition , San Diego, United States Of America, pp.272, 2023
Abboud, M. R. Et Al. (2023) . "Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study." 65th American Society of Hematology (ASH) Annual Meeting and Exposition , San Diego, United States Of America, p.272.
@conferencepaper{conferencepaper, author={Miguel R Abboud Et Al. }, title={Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study}, congress name={65th American Society of Hematology (ASH) Annual Meeting and Exposition}, city={San Diego}, country={United States Of America}, year={2023}, pages={272} }